Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome
Cancer Reports · 2024
DOI: 10.1002/cnr2.2145 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, 2024. Verfasst von Soichiro Minami und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoadjuvant Therapy, Cytokine Release Syndrome, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The expansion of preoperative immunochemotherapy has led to an increase in the number of patients with lung cancer receiving immune checkpoint inhibitors (ICIs). Therefore, oncologists should manage a variety of immune‐related adverse events (irAEs). One of the rare, life‐threatening, and recently proposed irAEs is cytokine release syndrome (CRS). Although the standard treatment of irAE is systemic administration of steroids, it has been suggested that tocilizumab may be an effective treatment option for CRS. Case This case describes a 69‐year‐old man with stage IIIA lung adenocarcinoma who received chemotherapy and nivolumab, which is an ICI, as neoadjuvant immunochemotherapy. After the first administration, the patient developed severe skin rash, fever, and arthralgia. We suspected irAEs and administered systemic steroids. However, fever and arthralgia did not improve, although the skin rash disappeared. These were also significant challenges for surgery. Noting the elevated levels of inflammatory cytokines, we consulted a rheumatologist. Finally, we decided to terminate neoadjuvant therapy after one cycle and administer tocilizumab. Tocilizumab dramatically improved the patient's symptoms and allowed him to undergo radical surgery. Pathological findings revealed that the patient achieved a major pathological response.
Conclusion
This indicates the potential effectiveness of early tocilizumab administration for ICI‐induced CRS, even in mild cases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Sendai Kousei Hospital, Sendai, Miyagi, Japan.
- Munakata Yasuhiko Clinic, Sendai, Miyagi, Japan.
- Department of Thoracic Surgery, Sendai Kousei Hospital, Sendai, Miyagi, Japan.
ORCID-Profile: Yosuke Kawashima
Zitieren
APA
Minami, S., Kawashima, Y., Munakata, Y., Matsuno, M., Hara, S., Yamazaki, Y., Doman, T., Saito, S., Odaka, T., Ogasawara, T., Shimizu, H., Sugisaka, J., Aiba, T., Toi, Y., Yamanda, S., Kimura, Y., & Sugawara, S. (2024). Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome. Cancer Reports. https://doi.org/10.1002/cnr2.2145
Vancouver
Minami S, Kawashima Y, Munakata Y, Matsuno M, Hara S, Yamazaki Y, et al. Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome. Cancer Reports. 2024. doi:10.1002/cnr2.2145
BibTeX
@article{Minami2024,
author = {Minami, Soichiro and Kawashima, Yosuke and Munakata, Yasuhiko and Matsuno, Masahiro and Hara, Shuichiro and Yamazaki, Yusuke and Doman, Tsuyoshi and Saito, Shin and Odaka, Tetsuo and Ogasawara, Takahiro and Shimizu, Hisashi and Sugisaka, Jun and Aiba, Tomoiki and Toi, Yukihiro and Yamanda, Shinsuke and Kimura, Yuichiro and Sugawara, Shunichi},
title = {Successful Application of Tocilizumab in a Patient With Neoadjuvant Immunochemotherapy‐Induced Cytokine Release Syndrome},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.2145}
}
EUVIMED